Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thalidomide
Drug ID BADD_D02192
Description A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]
Indications and Usage For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
Marketing Status Prescription
ATC Code L04AX02
DrugBank ID DB01041
KEGG ID D00754
MeSH ID D013792
PubChem ID 5426
TTD Drug ID D0U7GK
NDC Product Code 59572-205; 59572-210; 59572-220; 59572-215; 69988-0052; 63818-0424; 17337-0301; 68554-0011
Synonyms Thalidomide | Sedoval | Thalomid
Chemical Information
Molecular Formula C13H10N2O4
CAS Registry Number 50-35-1
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Deep vein thrombosisThrombomodulinP07204T0858315235749; 7878634
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Genital swelling21.10.01.0100.001737%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
H1N1 influenza22.07.02.007; 11.05.03.0020.000302%Not Available
Posterior reversible encephalopathy syndrome17.13.02.007--
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Lacrimal structural disorder06.06.04.013--Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021--Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.005--Not Available
Candida infection11.03.03.021--
Sinus node dysfunction02.03.03.017--
Multiple organ dysfunction syndrome08.01.03.0570.001208%
Liver function test increased13.03.01.044--Not Available
Abdominal mass07.01.01.0030.000302%Not Available
Adenocarcinoma of colon16.13.01.010; 07.21.01.0080.001158%Not Available
Brain neoplasm malignant16.30.04.002; 17.20.04.0020.001812%Not Available
Ewing's sarcoma15.09.03.015; 16.29.03.0040.000302%Not Available
Full blood count decreased13.01.07.0040.023739%Not Available
Leprosy11.04.03.0010.002895%Not Available
Medulloblastoma17.20.02.006; 16.30.02.0060.000302%Not Available
Meningitis tuberculous17.06.10.005; 11.04.01.0120.000302%Not Available
Monoclonal immunoglobulin present13.06.05.0130.001158%Not Available
Clostridium difficile infection11.02.02.0090.004053%Not Available
Hepatic infection11.01.18.008; 09.01.08.0140.001158%
Gastric infection11.01.07.008; 07.19.03.0030.001158%Not Available
Ovarian epithelial cancer21.11.01.017; 16.12.04.0060.000302%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.001158%Not Available
Apparent death08.01.03.0620.001158%Not Available
Type 2 lepra reaction24.05.02.026; 11.04.03.004; 23.07.02.006; 10.01.03.0480.001158%Not Available
Human chorionic gonadotropin increased13.10.05.0240.016791%Not Available
The 23th Page    First    Pre   23 24    Next   Last    Total 24 Pages